Type 2 diabetes drug was found to have the potential in reducing liver fat in patients with non-alcoholic fatty liver disease (NAFLD) and high blood sugar, reveals a new study.
In people with Type 2 Diabetes, NAFLD is common and can progress to a severe liver disease known as non-alcoholic steatohepatitis.
Study Says Consuming Probiotics Reduce Liver Fat
Consuming probiotics for a month helps in diminishing fat accumulation in the liver finds new study.
Advertisement
‘Empagliflozin is the diabetic drug that can help decrease the buildup of fat in the liver.’
Tweet it Now
The middle-aged adults who received empagliflozin showed an average 16.2 to 11.3 percent decrease in liver fat post 20 weeks of treatment.
On the other hand, the control group showed only a minimal decrease from 16.4 to 15.6 percent, the findings revealed.
"Despite the fact that NASH may progress to cirrhosis of the liver and liver cancer, there are no approved medications for treating NASH or NAFLD, and agents like metformin, pioglitazone, and Vitamin E have had limited success in reducing liver fat," said Ambrish Mithal, Chair of the Division of Endocrinology and Diabetes at Medanta The Medicity Hospital, Gurugram.
![Liver Fat Maintains Sugar Levels in Blood, Says Animal Study]( "Liver Fat Maintains Sugar Levels in Blood, Says Animal Study")
Mice in whom an enzyme called histone deacetylase 3 (HDAC3) is deleted, have massively fatty livers, but lower blood sugar, a new study has revealed.
"Our results suggest that empagliflozin may help in treating NAFLD," Mithal added, in the paper presented at the Endocrine Society's 100th Annual meeting in Chicago.
Previous studies had established the potential of the diabetes drug empagliflozin in decreasing liver fat in rodents with a buildup of fat in the liver.
"While our findings do not prove that empagliflozin will help treat NAFLD or prevent NASH, the initial results are promising and open up the possibility that empagliflozin may provide additional benefits for patients with diabetes," Mithal said.
In the trial, the team included patients who were 40 years or older and had Type 2 diabetes and NAFLD.
They were randomly assigned to receive empagliflozin (10 milligrams per day) plus their standard medical treatment for Type 2 diabetes, such as metformin and/or insulin, or to receive only their standard treatment without empagliflozin (control group).
Empagliflozin was approved by the US Food and Drug Administration in 2014 for adults with Type 2 diabetes.
It primarily acts by increasing glucose excretion through the urine, thereby reducing blood glucose levels and body weight.
Source: IANS
"Despite the fact that NASH may progress to cirrhosis of the liver and liver cancer, there are no approved medications for treating NASH or NAFLD, and agents like metformin, pioglitazone, and Vitamin E have had limited success in reducing liver fat," said Ambrish Mithal, Chair of the Division of Endocrinology and Diabetes at Medanta The Medicity Hospital, Gurugram.
Liver Fat Maintains Sugar Levels in Blood, Says Animal Study
Mice in whom an enzyme called histone deacetylase 3 (HDAC3) is deleted, have massively fatty livers, but lower blood sugar, a new study has revealed.
Advertisement
"Our results suggest that empagliflozin may help in treating NAFLD," Mithal added, in the paper presented at the Endocrine Society's 100th Annual meeting in Chicago.
Previous studies had established the potential of the diabetes drug empagliflozin in decreasing liver fat in rodents with a buildup of fat in the liver.
"While our findings do not prove that empagliflozin will help treat NAFLD or prevent NASH, the initial results are promising and open up the possibility that empagliflozin may provide additional benefits for patients with diabetes," Mithal said.
In the trial, the team included patients who were 40 years or older and had Type 2 diabetes and NAFLD.
They were randomly assigned to receive empagliflozin (10 milligrams per day) plus their standard medical treatment for Type 2 diabetes, such as metformin and/or insulin, or to receive only their standard treatment without empagliflozin (control group).
Empagliflozin was approved by the US Food and Drug Administration in 2014 for adults with Type 2 diabetes.
It primarily acts by increasing glucose excretion through the urine, thereby reducing blood glucose levels and body weight.
Source: IANS
Regular Exercise Reduces Liver Fat, Improves Non-Alcoholic Fatty Liver Disease
A short, moderate and daily exercise regimen, regardless of volume or intensity, benefits obese and overweight adults who have non-alcoholic fatty liver disease.
Advertisement
 Gastrointestinal Hormones may Help Ease Symptoms of Liver DiseasesThe gastrointestinal hormone can measurably improve the symptoms of non-alcoholic fatty liver diseases, finds a new study. The treatment significantly reduced liver fat in liver diseases. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.